South Korea has started distributing stocks of the COVID-19 treatment remdesivir which have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August, its disease control agency said.
"Patients who are eligible for remdesivir are limited to severe patients with pneumonia and in need of oxygen therapy," the Korea Centers for Disease Control and Prevention (KCDC) said in a statement.
It did not disclose how many doses have been donated by the U.S. firm.